CAC
LLY icon

Core Alternative Capital’s Eli Lilly LLY Stock Holding History

Core Alternative Capital’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.8M Sell
8,484
-312
-4% -$316K 2.3% 8
2025
Q4 		$9.45M Sell
8,796
-3,124
-26% -$2.99M 2.61% 5
2025
Q3 		$9.1M Sell
11,920
-1,318
-10% -$981K 2.64% 5
2025
Q2 		$10.3M Sell
13,238
-1,355
-9% -$1.05M 2.82% 5
2025
Q1 		$12.1M Sell
14,593
-1,545
-10% -$1.29M 2.9% 6
2024
Q4 		$12.5M Buy
16,138
+324
+2% +$268K 2.6% 6
2024
Q3 		$14M Sell
15,814
-872
-5% -$784K 2.71% 6
2024
Q2 		$15.1M Sell
16,686
-1,755
-10% -$1.4M 3.02% 5
2024
Q1 		$14.3M Sell
18,441
-6,670
-27% -$4.75M 2.57% 5
2023
Q4 		$14.6M Sell
25,111
-11,468
-31% -$6.69M 2.51% 5
2023
Q3 		$19.6M Sell
36,579
-1,265
-3% -$652K 3.03% 4
2023
Q2 		$17.7M Sell
37,844
-14,249
-27% -$5.98M 2.6% 6
2023
Q1 		$17.9M Sell
52,093
-8,287
-14% -$2.79M 2.39% 10
2022
Q4 		$22.1M Buy
60,380
+3,972
+7% +$1.41M 2.81% 6
2022
Q3 		$18.2M Buy
56,408
+16,674
+42% +$5.28M 2.91% 4
2022
Q2 		$12.9M Buy
39,734
+6,452
+19% +$1.94M 3.04% 4
2022
Q1 		$9.53M Sell
33,282
-7,128
-18% -$1.83M 2.55% 5
2021
Q4 		$9.98M Sell
40,410
-1,033
-2% -$262K 2.01% 13
2021
Q3 		$9.57M Sell
41,443
-1,007
-2% -$249K 2.01% 13
2021
Q2 		$9.74M Buy
42,450
+5,518
+15% +$1.11M 2.26% 7
2021
Q1 		$6.9M Buy
36,932
+917
+3% +$179K 1.96% 14
2020
Q4 		$6.08M Buy
36,015
+1,941
+6% +$290K 1.82% 21
2020
Q3 		$5.04M Sell
34,074
-3,188
-9% -$493K 1.72% 33
2020
Q2 		$6.12M Sell
37,262
-3,771
-9% -$579K 1.91% 12
2020
Q1 		$5.69M Buy
41,033
+24,181
+143% +$3.32M 1.99% 12
2019
Q4 		$2.21M Buy
+16,852
New +$1.95M 2.03% 35

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Core Alternative Capital's LLY Position: Q1 2026 in Review

Core Alternative Capital reduced its Eli Lilly (LLY) stake by 3.5% in Q1 2026, selling an estimated $316K and leaving 8,484 shares worth $7.8M. The position accounts for 2.3% of the portfolio, ranked #8.

Core Alternative Capital first reported a position in LLY in Q4 2019 and has held it in 26 quarters since. The position peaked at $22.1M in Q4 2022. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Core Alternative Capital held 8,484 shares of Eli Lilly worth $7.8M as of Q1 2026.
  • Core Alternative Capital sold 312 Eli Lilly shares in Q1 2026, an estimated $316K.
  • Eli Lilly made up 2.3% of Core Alternative Capital's portfolio in Q1 2026, its #8 holding.
  • Core Alternative Capital first reported a position in Eli Lilly in Q4 2019 and has held it in 26 quarters since.
  • Core Alternative Capital's Eli Lilly position peaked at $22.1M in Q4 2022.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Core Alternative Capital's 13F filing for Q1 2026, filed 30 Apr 2026.